Will Abivax announce the initiation of a Phase 3 clinical trial for its bowel disease drug (ABX464) by December 31, 2028?

The recent trial update caused a significant stock drop, suggesting potential setbacks or re-evaluation. A quick progression to Phase 3 would indicate strong confidence in the drug despite the recent news, while delays would suggest further challenges.

Implied probability (Yes)

35%

Closes

2030-08-31